| Business Summary | | BioTransplant
Incorporated
is
developing
pharmaceutical
products
and
systems
to
enable
the
body's
immune
system
to
better
tolerate
the
transplantation
of
foreign
cells,
tissues
and
organs.
Its
lead
product,
MEDI-507,
is
being
developed
in
collaboration
with
MedImmune,
Inc.
The
Company
is
also
independently
developing
other
proprietary
technology,
which
it
refers
to
as
ImmunoCognance
technology.
This
technology
is
based
upon
mixing
elements
of
a
donor's
immune
system
with
that
of
a
patient
in
a
manner
that
enables
the
patient
to
recognize
the
donor's
tissues
as
if
those
foreign
tissues
belonged
to
the
patient.
Based
upon
its
ImmunoCognance
technology,
the
Company
is
developing
a
portfolio
of
products
designed
to
improve
therapies
associated
with
organ
and
bone
marrow
transplantation,
as
well
as
to
improve
the
treatment
of
cancer,
autoimmune
diseases
and
blood
disorders. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BioTransplant
Incorporated
develops
proprietary
anti-rejection
pharmaceuticals
and
organ
transplantation
systems,
which
represent
a
comprehensive
approach
to
inducing
long-term
specific
transplantation
tolerance
in
humans.
For
the
three
months
ended
3/31/01,
revenues
totaled
$0,
down
from
$1.5
million.
Net
loss
fell
7%
to
$2.3
million.
Revenues
reflect
the
termination
of
research
agreement.
Net
loss
reflects
decreased
R&D
expenses
due
to
reimbursements. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
after
tax
earnings
were
-3,703. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Elliot Lebowitz, Ph.D., 60 Chairman,
CEO | $309K | -- | Walter Ogier, 44 Pres,
COO, Director | -- | -- | James Hope, Ph.D., 49 Sr.
VP of Devel. | 229K | $146K | Mary White-Scharf, Ph.D., 50 Sr.
VP, Research | 191K | 147K | Richard Capasso, 39 VP,
Fin. and Treasurer | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|